NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Gympass, the world's largest corporate fitness platform, today announced the launch of a new Technology Hub following the acquisition of Flaner, an emerging digital memory extension platform based in Lisbon, Portugal. Flaner's artificial intelligence and machine learning technology will create personalized experiences for Gympass users, corporate clients and fitness partners.

This acquisition is one of several initiatives led by Gympass to develop game-changing technology at the intersection of corporate wellness and physical activity. The new Tech Hub includes current Flaner employees and will quickly expand to a team of up to 50. Both the recently opened New York Tech Hub and the Lisbon Tech Hub will focus on leveraging AI to improve user experiences across Gympass' three-sided marketplace.

"We are thrilled to acquire Flaner's proven Artificial Intelligence technology and experienced product development talent. This strategic partnership will further our vision to deliver intuitive customer experiences, both globally and at scale," says Gympass CEO and Co-Founder Cesar Carvalho. "These strides in product and technology will help Gympass users easily find activities they love, creating a happier, healthier and more productive society."

Gympass partners with over 2,000 clients worldwide, including Citizens Bank, Santander, and University of Southern California, offering employees access to over 50,000 gyms and studios across 14 countries. Flaner's founding team brings almost 50 years of technology experience at Google and leading Latin American technology companies UOL and B2W. The team is comprised of machine learning, data retrieval, and artificial intelligence experts who will bring their knowledge in building, innovating, and scaling world-class products to Gympass' growing ecosystem.

"We are excited to join Gympass on its mission to defeat the global pandemic of physical inactivity," said Victor Ribeiro, CEO and Founder of Flaner. "At Flaner, we have always created products that significantly improve lives. Now with Gympass' unique offering, we can apply our expertise to positively change the lives of millions through innovative technology."

Carvalho continues: "Flaner's agile, high-growth team will be a great complement to our existing technology teams to make corporate wellness programs and flexible fitness options a reality for everyone."

About Gympass:

On a mission to defeat inactivity, Gympass helps companies revolutionize how inactive employees engage in physical activity, driving lasting behavioral change. Our 2000+ clients credit Gympass' unmatched variety, convenience, and flexibility with helping to improve employee engagement, individual performance, and overall business success.

Across 14 countries and over 50,000 gym and studio partners, Gympass partners with corporations to craft ongoing, personalized programs that will inspire your workforce to enroll, stay motivated and unlock their full potential.

For more information, please contact Alex Edel at alexandra.edel@gympass.com.

SOURCE: Gympass

ReleaseID: 570375

ReleaseID: 570360

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Pareteum Corporation (NASDAQ:TEUM)

Investors Affected : December 14, 2017 – October 21, 2019

A class action has commenced on behalf of certain shareholders in Pareteum Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) it was not true that the Company’s purported success was the result of hyper-demand for Pareteum’s unique products or exceptional service, or the Company’s competent management; but, in fact, Defendants had propped up the Company’s results by manipulating Pareteum’s accounting for revenues, income, and the important Backlog metric; (b) Defendants had materially overstated the Company’s profitability by failing to properly account for the Company’s results of operations and by artificially inflating the Company’s financial results; (c) it was not true that Pareteum contained even the most minimally adequate systems of internal operational or financial controls necessary to assure that Pareteum’s reported financial statements were true, accurate, and/or reliable; (d) as a result, it also was not true that the Company’s financial statements and reports were prepared in accordance with GAAP and SEC rules; and (e) as a result of the aforementioned adverse conditions, Defendants lacked any reasonable basis to claim that Pareteum was operating according to plan, or that Pareteum could achieve the guidance sponsored and/or endorsed by Defendants.

Shareholders may find more information at https://securitiesclasslaw.com/securities/pareteum-corporation-loss-submission-form/?id=4902&from=1.

Under Armour, Inc. (NYSE:UA)

Investors Affected : August 3, 2016 – November 1, 2019

A class action has commenced on behalf of certain shareholders in Under Armour, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) undisclosed to the investing public, the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/under-armour-inc-loss-submission-form/?id=4902&from=1

Resideo Technologies, Inc. (NYSE:REZI)

Investors Affected : October 29, 2018 – October 22, 2019

A class action has commenced on behalf of certain shareholders in Resideo Technologies, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the negative operational effects of the Company's spin-off from Honeywell International Inc. were more substantial and persistent than disclosed and had negatively affected Resideo’s product sales, supply chain, and gross margins, putting the Company’s FY19 financial forecasts at risk; and (b) as a result of the foregoing, the Company’s financial guidance lacked a reasonable basis and the Company was not on track to make its FY19 guidance as claimed.

Shareholders may find more information at https://securitiesclasslaw.com/securities/resideo-technologies-inc-loss-submission-form/?id=4902&from=1.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 570367

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Abeona Therapeutics Inc. (NASDAQ:ABEO)

Class Period: May 31, 2018 – September 23, 2019

Deadline: January 2, 2020
For more info: www.bgandg.com/abeo

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Abeona's Chemical, Manufacturing and Controls ("CMC") and internal controls and procedures and/or compliance policies were inadequate; (2) as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient; (3) consequently, it was foreseeable that the U.S. Food and Drug Administration ("FDA") would reject approval for the start of the VITAL Study until such issues were addressed; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

AZZ, Inc. (NYSE:AZZ)

Class Period: July 3, 2018 – October 8, 2019

Deadline: January 3, 2020
For more info: www.bgandg.com/azz

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AZZ's internal controls over financial reporting were not effective; (2) AZZ improperly implemented ASC 606 which resulted in improper revenue reconciliations; and (3) as a result of the foregoing, defendants' positive statements about AZZ's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Twitter, Inc. (NYSE:TWTR)

Class Period: August 6, 2019 – October 23, 2019

Deadline: December 30, 2019
For more info: www.bgandg.com/twtr

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) while Twitter represented that it "fixed" certain issues relating to user choice settings designed to target advertising were not working as intended; (2) the changes implemented to fix these issues adversely affected Twitter's ability to target advertising, including the targeting of advertising through its Mobile App Promotion ("MAP") product, which caused a material decline in advertising revenue; and (3) as a result, Twitter's public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570312

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)
Class Period: August 8, 2017 to September 30, 2019
Lead Plaintiff Deadline: February 10, 2020

The ADMS lawsuit alleges that Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Learn about your recoverable losses in ADMS: http://www.kleinstocklaw.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?id=4904&from=1

X Financial (NYSE:XYF)
Class Period: X Financial American Depositary Shares pursuant and/or traceable to the Company's September 19, 2018 initial public offering.
Lead Plaintiff Deadline: February 7, 2020

The XYF lawsuit alleges X Financial made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Company's total loan facilitation amount was not growing, but rather was contracting; (ii) the number of investors actively using X Financial's platform was shrinking; (iii) demand from small- and medium-sized enterprises for the Company's preferred loans was plummeting; (iv) the Company's preferred loans had performed so poorly that it had begun drastically scaling back its preferred loans in the first quarter of 2018, several months before the initial public offering ("IPO"), and was in the process of phasing out such loans completely; (v) demand for the Company's card loans was also plummeting; (vi) the revenue and loan facilitation growth provided in the registration statement leading up to the IPO was achieved by relaxed credit and due diligence standards, under which the Company had underwritten tens of millions of dollars' worth of poor quality loans that suffered from a disproportionately high risk of default as compared to the Company's earlier loan vintages; (vii) the Company was suffering from accelerated delinquency rates from poor quality loans that it had underwritten in the first, second, and third quarters of 2018, which had caused the Company's delinquency rate to sharply rise; (viii) the Company's product mix had significantly deteriorated; (ix) the Company's net revenue was on track to decline by 22% during the third quarter of 2018; and (x) as a result, the Registration Statement was materially false and/or misleading and failed to state information required to be stated therein.

Learn about your recoverable losses in XYF: http://www.kleinstocklaw.com/pslra-1/x-financial-loss-submission-form?id=4904&from=1

Baozun Inc. (NASDAQ:BZUN)
Class Period: Baozun American Depository Receipts between March 6, 2019 and November 20, 2019
Lead Plaintiff Deadline: February 10, 2020

Baozun Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) Baozun was heavily reliant upon a single brand partner, Huawei, for the exponential service fee growth it had been reporting historically, which was in turn fueling its historical revenue growth; (b) compared to other brands Baozun had as brand partners, the Huawei work had historically included a lot of additional add-on service fees, increasing the revenue reported from Huawei vis-a-via its other brand partners; (c) Huawei, like other large brands, was actively preparing to bring its online merchandising in-house, meaning Baozun knew that it was losing a significant brand partner; and (d) as a result of the foregoing, the Company was not on track to achieve the financial results and performance Defendants claimed the Company was on track to achieve during the class period.

Learn about your recoverable losses in BZUN: http://www.kleinstocklaw.com/pslra-1/baozun-inc-loss-submission-form?id=4904&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 570369

New IC enables direct LED lamp control using advanced networking interface capability

DORTMUND, GERMANY / ACCESSWIRE / December 16, 2019 / Elmos Semiconductor AG and Audi AG extend their long lasting partnership for LED rear light control. The partners announce sample availability of the new Elmos IC E522.95. This multichannel LED controller for exterior lighting with advanced network interface capabilities allows direct control of LED lamps. Equipped with a 2Mbps CAN FD protocol and a CAN FD physical interface, the E522.95 can be connected directly to the Body Control Unit (BCM) via the car in-vehicle network – therefore local lighting control units are no longer needed.

"Enabling direct control between the BCM and LED lamps marks an important step towards realizing centralized car lighting and domain driven architectures considered essential for styling, customization, dynamic animation and autonomous drive by removing the need of localized lighting control units and thereby resulting into significant system cost savings and above all full application flexibility." said Dr. Klaus Büttner, Executive Vice President Electrics/Electronics, CarIT of the Audi AG.

Developed fully according to the ISO26262 Functional Safety development process, the E522.95 offers a full suite of diagnosis features that ensure reliable system operation of LED drivers and enable achieving ASIL-B ratings at system level. The 16 channel E522.95 LED controller has a maximum output current of 100mA per channel and supports Elmos' patented power management methodology ensuring a constant light intensity of the LEDs even under difficult thermal conditions. The E522.95 is offered in a QFN40 package with an exposed die pad.

"The introduction of the E522.95 marks a significant step in our collaboration with Audi in bringing innovative system solutions based on our expertise in in-vehicle network interfaces. We are pleased to see that our joint efforts result in solutions allowing new features for the end users while at the same time cost savings at the OEM." said Dr. Anton Mindl, CEO Elmos Semiconductor AG.

For further product information, datasheet, evaluation kits and engineering samples, please contact sales@elmos.com with "E522.95" in the subject line or contact us by telephone: + 49 231 7549 100.

The product features of the E522.95 will also be shown at the CES (Las Vegas, 7-10 January 2020). You will find Elmos in the Westgate Tower (Suite #19121), adjacent to the CES Congress Center.

About Elmos Semiconductor AG

Elmos develops, produces and markets semiconductors and sensors, primarily for use in the automotive industry. Our components communicate, measure, regulate and control safety, comfort, powertrain and network functions. For over 30 years, Elmos innovations have been bringing new functions to life and making mobility worldwide safer, more comfortable and more energy efficient.

Contact

Elmos Semiconductor AG
Janina Rosenbaum, Head of Investor Relations, Fon: +49231‐7549‐287
Mathias Kukla, Press Relations, Fon: +49231‐7549‐199
Email: invest@elmos.com

SOURCE: Elmos Semiconductor AG

ReleaseID: 570361

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Up Fintech Holding Limited (NASDAQ:TIGR)

Class Period: (1) pursuant and/or traceable to Up Fintech's initial public offering conducted on or about March 20, 2019 (the "IPO" or "Offering"); or (2) between March 20, 2019 and May 16, 2019, both dates inclusive (the "Class Period")

Deadline: January 6, 2020
For more info: www.bgandg.com/tigr

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Fintech was experiencing a material decrease in commissions because of a negative trend related to risk-averse investors in the market; (2) Fintech was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (3) Fintech was incurring significant additional expenses related to, inter alia, employee headcount and employee compensation and benefits; (4) all of the foregoing had led to Fintech significantly increasing operating costs and expenses; and (5) as a result, defendants' statements regarding Up Fintech's business, operations, and prospects, were materially false and misleading.

Under Armour, Inc. (NYSE:UA; UAA)

Class Period: August 3, 2016 – November 1, 2019,

Deadline: January 6, 2020
For more info: www.bgandg.com/uaa

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Quad/Graphics, Inc. (NYSE:QUAD)

Class Period: February 21, 2018 – October 29, 2019

Deadline: January 6, 2020
For more info: www.bgandg.com/quad

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's book business in United States was underperforming; (2) as a result, the Company was likely to divest its book business; (3) the Company was unreasonably vulnerable to decreases in market prices; (4) to remain financially flexible while market prices decreased, the Company was likely to cut its quarterly dividend and expand its cost reduction programs; and (5) as a result of the foregoing, positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570311

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Correvio Pharma Corp. ("Correvio" or the Company") (NASDAQ:CORV) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Correvio securities between October 23, 2018 and December 5, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/corv.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting the Resubmitted New Drug Application ("NDA") for Brinavess did not minimize the significant health and safety issues observed in connection with the drug's original NDA; (2) the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) as a result, Correvio's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/corv or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Correvio you have until February 10, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 570333

JUPITER, FL / ACCESSWIRE / December 16, 2019 / GelTech Solutions, Inc. (OTC PINK:GLTC), a leader environmentally-friendly products and firefighting agents is pleased to report that Sabre Industries, Inc., an industry leader in utility and telecommunication tower design, construction and modification is taking a lead role in tower modification fire safety by mandating the use of FireIce Shield CTP for all hot work on a national level.

Sabre Industries, Inc. recognizes the value of asset protection benefits and limiting risk exposure, while performing hot work. While performing modification to communication towers, the characteristics of FireIce Shield CTP reduces that risk in an environmentally friendly, cost effective method.

FireIce Shield CTP gel is a proprietary gel, by GelTech Solutions, that minimizes risk of damage caused by welding sparks, fire, slag and heat damage, by creating a temporary thermal barrier that can withstand temperatures in excess of 5000 degrees F. This protects the tower, interior cables and the surrounding area.

"Sabre is excited to partner with GelTech on this safety initiative and provide the reassurance to our contractors, tower owners, and carriers that preventative measures are a safety priority for our company," stated Thomas Pallas, SVP Telecom Services for Sabre Site Services, a Division of Sabre Industries, Inc.

"We very much appreciate the effort and collaboration Sabre Industries, Inc. has provided in helping us develop this program to greatly reduce fires resulting from the performance of hot work on communication towers," stated Michael Reger, CEO of GelTech. "The use of our FireIce Shield CTP product helps improve workers safety, protects the tower and its communications equipment, thus safeguarding the revenue stream of the tower owner."

About Sabre Industries, Inc.

Sabre Industries, Inc., provides highly engineered support structures used in electric transmission and distribution, telecommunication, renewable energy, and government infrastructure. In addition, they offer a variety of value-added services that are critical to the development, expansion and maintenance of both power delivery systems and telecommunication networks.

About GelTech Solutions, Inc.

Founded by inventor and Chief Technology Officer, Peter Cordani, GelTech Solutions is a leading provider of innovative, environmentally friendly and cost-effective products that help government agencies, industry, agriculture and the public achieve goals such as water conservation and protecting lives, homes and property from fires.

Sabre Industries, Inc. is looking forward to the future of this partnership with GelTech.

For more information please visit: www.SabreIndustries.com, follow us on Facebook @ facebook.com/Sabreindustries.

Media Contact:

Kristin Burbank
Executive Administrative Assistant, Sabre Industries, Inc.
712.224.1594 | kburbank@sabreindustries.com

For more information please visit geltechsolutions.com, follow us on Twitter @GelTechSol, or find us on LinkedIn at www.linkedin.com/company/geltechsolutions.

Media Contact:

Paul Christle
Director of Communications, GelTech
561.427.6144 | info@geltechsolutions.com

SOURCE: GelTech Solutions. Inc.

ReleaseID: 570357

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zynerba Pharmaceuticals, Inc. ("Zynerba" or the "Company") (NASDAQ:ZYNE) and certain of its officers, on behalf of shareholders who purchased Zynerba securities between March 11, 2019, and September 17, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/zyne.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

On September 18, 2019, during pre-market hours, Zynerba issued a press release announcing results from the BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with DEE (the "September 2019 Press Release"). While Zynerba asserted that Zygel was well-tolerated in the September 2019 Press Release, it also disclosed that, among patients enrolled in the BELIEVE 1 Trial, the rate of treatment emergent adverse events ("TEAEs") was 96%, the rate of treatment related adverse events ("TRAEs") was 60%, and there were ten patients who reported serious adverse events ("SAEs"), of which, "two SAEs (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment." Following this news, Zynerba's stock price fell $2.46 per share, or 21.77%, to close at $8.84 per share on September 18, 2019.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/zyne or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Zynerba you have until December 23, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 570309